Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

NCT07672561 is registered in ClinicalTrials.gov with Zhejiang Wenda Pharma Technology LTD. as lead sponsor.

NCT NCT07672561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07672561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
Lead sponsor
Zhejiang Wenda Pharma Technology LTD.
Phase
Phase 3
Overall status
Recruiting
Start date
March 18, 2026
Completion date
July 30, 2027
Enrollment
375 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe plaque psoriasis